Blue Trust Inc. Sells 5,948 Shares of Sanofi (NASDAQ:SNY)

Blue Trust Inc. trimmed its stake in Sanofi (NASDAQ:SNY - Free Report) by 33.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,098 shares of the company's stock after selling 5,948 shares during the quarter. Blue Trust Inc.'s holdings in Sanofi were worth $583,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in SNY. Franklin Resources Inc. lifted its stake in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after acquiring an additional 395,744 shares during the last quarter. Natixis Advisors LLC lifted its stake in Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company's stock valued at $165,640,000 after purchasing an additional 114,133 shares during the last quarter. Raymond James & Associates grew its holdings in Sanofi by 4.8% during the third quarter. Raymond James & Associates now owns 2,819,348 shares of the company's stock worth $162,479,000 after purchasing an additional 129,472 shares during the period. JPMorgan Chase & Co. increased its position in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, DAVENPORT & Co LLC raised its stake in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after buying an additional 664,455 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Stock Performance

SNY traded down $0.35 during trading on Wednesday, hitting $53.60. The stock had a trading volume of 2,752,318 shares, compared to its average volume of 2,513,554. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market cap of $136.03 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 1.02 and a beta of 0.57. The company has a 50 day moving average price of $50.65 and a 200-day moving average price of $52.49. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.